A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Non-small cell lung cancer; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 27 Aug 2018 Planned End Date changed from 31 May 2021 to 31 Aug 2022.
- 27 Aug 2018 Planned primary completion date changed from 31 May 2021 to 31 Aug 2022.
- 24 Aug 2018 Planned End Date changed from 29 Jun 2021 to 31 May 2021.